A recent study led by researchers at Auburn University has highlighted the potential of a novel drug, troriluzole, in preventing early-stage brain changes associated with Alzheimer’s disease, Neuroscience News reports.
The research, published in the Journal of Neurochemistry, demonstrated that troriluzole effectively reduces harmful levels of glutamate in a mouse model, preserving memory and cognitive function.
The study represents a significant step forward, as it is the first to show that troriluzole can address early alterations linked to Alzheimer’s. This finding opens new avenues for potential treatments aimed at slowing or halting the disease’s progression.
Dr. Miranda Reed, a professor in Auburn’s Department of Drug Discovery and Delivery and the study’s lead researcher, explained that the goal of their research is to develop therapies that could prevent or potentially cure Alzheimer’s by intervening early in the disease process.
“This study also highlights how scientific advancements can transform our understanding of complex diseases like Alzheimer’s,” added Dr. Michael Gramlich, Assistant Professor of Biophysics and co-researcher.
Research Findings
Alzheimer’s disease, which affects millions globally, is characterized by progressive memory loss and cognitive decline, linked to the accumulation of amyloid plaques and tau tangles in the brain. In its early stages, excessive glutamate—a neurotransmitter—can lead to overactivity in synapses, impairing brain function.
In the Auburn University study, researchers investigated how troriluzole might counteract these early-stage changes. The drug was shown to lower glutamate levels and reduce brain hyperactivity in genetically modified mice, which replicate early Alzheimer’s stages. The treated mice exhibited improved memory and learning abilities, suggesting that troriluzole helps maintain healthy brain function.
“Our research demonstrates that by targeting synaptic activity early, we may be able to prevent or slow the progression of Alzheimer’s,” said Dr. Reed.
“This could revolutionize the way we approach treatment for this disease,” added Dr. Gramlich.
Mechanism of Action
Troriluzole works by reducing synaptic glutamate levels and decreasing brain hyperactivity. Mice receiving the drug performed better in memory tests, such as navigating mazes, indicating restored cognitive function.
“These findings are promising because they suggest that troriluzole can protect the brain at a fundamental level, leading to improved cognitive abilities,” said Dr. Reed.
